SUBCUTANEOUS VS INTRAVENOUS ADMINISTRATION OF TRASTUZUMAB IN HER2+BREAST CANCER PATIENTS: A MACEDONIAN COST-MINIMIZATION ANALYSIS

被引：2
|
作者：
Nestorovska, A. [1 ]
Naumoska, Z. [1 ]
Grozdanova, A. [1 ]
Stoleski, D. [2 ]
Ivanovska, A. [2 ]
Risteski, M. [3 ]
Vasev, N. [3 ]
Ismaili, I. [3 ]
Stefanovski, P. [4 ]
Dimovski, A. [1 ]
Suturkova, L. [1 ]
Sterjev, Z. [5 ]
机构：
[1] ISPOR Republ Macedonia Reg Chapter, Skopje, Macedonia
[2] DOOEL, Roche Macedonia, Skopje, Macedonia
[3] Univ Clin Radiotherapy & Oncol, Skopje, Macedonia
[4] Clin Hosp, Bitola, Macedonia
[5] UKIM Skopje, Fac Pharm, Skopje, Macedonia
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1205
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN188
引用
收藏
页码：A463 / A463
页数：1
相关论文
共 50 条
  • [41] A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer
    De Cock, Erwin
    Pivot, Xavier
    Hauser, Nik
    Verma, Sunil
    Kritikou, Persefoni
    Millar, Douglas
    Knoop, Ann
    CANCER MEDICINE, 2016, 5 (03): : 389 - 397
  • [42] Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer
    Wynne, Chris
    Harvey, Vernon
    Schwabe, Christian
    Waaka, Devonie
    McIntyre, Christine
    Bittner, Beate
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (02): : 192 - 201
  • [43] HOSPITAL CAPACITY TOOL TO ASSESS THE POTENTIAL IMPACT OF USING A FIXED DOSE COMBINATION OF PERTUZUMAB/TRASTUZUMAB FOR SUBCUTANEOUS INJECTION VERSUS INTRAVENOUS PERTUZUMAB/ TRASTUZUMAB IN HER2+BREAST CANCER
    Cunha, A.
    VALUE IN HEALTH, 2023, 26 (12) : S296 - S296
  • [44] ANALYSIS OF MINIMIZATION OF COSTS OF THE USE OF SUBSTITUTE TRASTUZUMAB FOR INTRAVENOUS TRASTUZUMAB IN THE TREATMENT OF EARLY BREAST CANCER IN WOMEN WITH HER2 POSITIVE FOR VENEZUELA
    Romero, M.
    Acero, G.
    Huerfano, L. M.
    VALUE IN HEALTH, 2015, 18 (07) : A823 - A823
  • [45] AXL is a potential druggable target in trastuzumab resistance in HER2+breast cancer patients.
    Adam-Artigues, Anna
    Cervera, Raimundo
    Javier Arenas, Enrique
    Braso-Maristany, Fara
    Martinez-Sabadell, Alex
    Tormo, Eduardo
    Hernando, Cristina
    Teresa Martinez, Maria
    Simon, Soraya
    Poveda, Jesus
    Burgues, Octavio
    Rovira, Ana
    Rojo, Federico
    Albanell, Joan
    Bermejo, Begona
    Lluch, Ana
    Eroles, Pilar
    Prat, Aleix
    Arribas, Joaquin
    Miguel Cejalvo, Juan
    CANCER RESEARCH, 2021, 81 (13)
  • [46] Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
    Simoens, Steven
    Vulto, Arnold G.
    Dylst, Pieter
    PHARMACEUTICALS, 2021, 14 (05)
  • [47] Cost minimization analysis of treatments for metastatic HER2-positive breast cancer in Peru: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injections
    Figallo, Miguel
    Delgado, Maria F.
    Gonzalez, Mauricio
    Arenas, Adrian
    PLOS ONE, 2024, 19 (11):
  • [48] Adjuvant trastuzumab and vinorelbine for early-stage HER2+breast cancer
    McLaughlin, Shannon
    Nakajima, Erika
    Bar, Yael
    Hutchinson, Jennifer A. A.
    Shin, Jennifer
    Moy, Beverly
    Isakoff, Steven J. J.
    Bardia, Aditya
    Kuter, Irene
    Spring, Laura M. M.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [49] Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+Breast Cancer
    Song, Patrick N.
    Mansur, Ameer
    Lu, Yun
    Della Manna, Deborah
    Burns, Andrew
    Samuel, Sharon
    Heinzman, Katherine
    Lapi, Suzanne E.
    Yang, Eddy S.
    Sorace, Anna G.
    CANCERS, 2022, 14 (04)
  • [50] Adjuvant and neoadjuvant trastuzumab in combination with vinorelbine for HER2+breast cancer.
    Esfahani, Khashayar
    Ferrario, Cristiano
    Le, Philippe
    Panasci, Lawrence C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345